About Us

core_expertise_about_inset

Our Core Areas of Expertise

  • Turnaround of underperforming businesses
  • Transforming businesses to scale and progress to the next level
  • Strategic assessment and alignment to operating plans to produce results
  • Improving sales performance and process
  • Commercialization and new technology launch
  • Strategic Assessment, diligence and integration for business development and M&A

We have many other core competencies and resources to support our clients. Our process is simple and adaptable to most crucial situations, producing common-sense solutions that deliver the desired results. We look forward to working with you.

Partners

Thomas J. Dugan

(203) 417-3850 | [email protected] | vCard

Tom is an experienced C-level executive who has transformed businesses, established new market opportunities, and driven growth in the face of strong competition. He understands how to promote growth by building organizational capabilities, developing effective strategies, optimizing product portfolios, developing innovative go-to-market models, and establishing processes for effective management.

Tom serves as Chairman of the Board of Directors for BioStem Technologies, Inc., a leader in amniotic tissue-based regenerative medicine therapies, and TYBR Health, a start-up focused on the prevention of surgical adhesions.

He has a strong track record as CEO/President of companies including, Integrum, Amniox Medical, SurgiQuest, Smith & Nephew, and SonoSite. Tom’s formative years were spent at Johnson & Johnson, CR Bard, and US Surgical/Tyco Healthcare.

Tom brings proven, hands-on experience as a senior executive who has transformed businesses, established new market opportunities, and driven growth in the face of strong competition. His extensive leadership experience across start-ups to larger corporate organizations helps him recognize and optimize business value. Tom understands how to promote growth by building organizational capabilities, optimizing product portfolios, developing innovative go-to-market models, and establishing processes for effective management.

Throughout his career, Tom has led successful businesses in virtually every clinical segment of the medical device and regenerative medicine markets. More importantly, he drove disruption in multi-billion-dollar markets creating unique new market segments such as point-of-care ultrasound, disposable negative pressure wound therapy, intelligent access systems for robotic and laparoscopic surgery, orthopedic osseointegration, and the clinical application of human placental tissues.

As a co-founder of 360 Life Sciences Advisors, Tom works with private equity and venture capital firms to assess new investment opportunities and improve performance at portfolio companies. His role as a counselor to both start-ups and established companies involves providing strategic, commercial, and operational guidance to address various challenges. Tom serves as Chairman of the Board of Directors of BioStem Technologies, Inc., a leader in amniotic tissue-based regenerative medicine therapies. He is also Chairman of the Board for TYBR Health, a start-up focused on prevention of surgical adhesions.

He was President of Integrum, Inc., the pioneer in osseointegrated orthopedic implants that improve the lives of those with limb loss. Serving as the CEO and board member of Amniox Medical (BioTissue, Inc.), the pioneer and leader in the clinical application of human placental tissues in wound care and orthopedic surgery, he transformed the company implementing processes, systems, and personnel changes leading to significant growth and access to new market segments. Tom was the President and board member of SurgiQuest, a start-up that revolutionized access management in robotic and laparoscopic surgery, which was acquired by ConMed for $265M. At Smith & Nephew Tom was President of Americas and served on the Global Executive Management team of the $1.3 billion wound management business. He led a turnaround, driving growth at over twice the market rate, and established Smith & Nephew as a leading player in the negative pressure wound therapy market against a strong monopoly. Previously Tom served as Senior Vice President at SonoSite, the world leader in point-of-care ultrasound, with responsibility for the U.S. business, worldwide marketing, business development, and investor relations. He drove growth over 20% annually leading to SonoSite’s acquisition by Fujifilm for $995M.

Tom also served as President of InterVascular, Inc. and Corporate Vice President of Business Development of Datascope. He was the Vice President of Marketing at U.S. Surgical/Tyco Healthcare (now Covidien/Medtronic) and ran business development during a period of significant M&A activity with multiple acquisitions and divestitures that transformed the corporation. Earlier in his career, Tom held various sales, marketing, and international positions of increasing responsibility with C.R. Bard, Puritan-Bennett, and Johnson & Johnson.

He also worked with the Life Sciences Incubator at the Mayo Clinic to create and mentor leadership teams of newly formed companies. Tom served on the board of directors of Rita Medical Systems (NASDAQ: RITA), which was acquired by AngioDynamics, and various venture-backed medical device companies. He chaired the Wound Healing and Tissue Regeneration sector of AdvaMed and served on the board of MITA, the industry trade group for medical imaging.

Sean McNerney

(203) 252-9082 | [email protected] | vCard

Sean is a seasoned leader in the medical device space with significant commercialization expertise in launching new and novel technologies. Sean has held executive positions across small, medium and large companies in general management, marketing, sales and business development.

He has worked for global companies such as US Surgical, Covidien, LivaNova as well as start-ups. Sean’s leadership skills have earned him accolades for steering large and complex organizations through periods of accelerated growth, turnarounds, and acquisition integrations.

CEO, Board Member, President, VP Sales & Marketing, VP Sales, Various Marketing and Sales roles

As co-founder of 360 Life Sciences Advisors, Sean has a passion for defining vision while positioning entrepreneurial, early-stage, and midsize U.S./global businesses for record performance.

As CEO of Origami Surgical, Sean built the infrastructure of this startup company from A-Round to full commercialization. He expanded the portfolio from one to ten products, including five FDA clearances. He expanded the IP portfolio to protect the technology for future development.

Prior to this, Sean was the U.S. President for the Sorin Group (now LivaNova), a medical technology company specializing in cardiac devices for surgery. In this role, he held General Manager level, P&L accountability for the U.S. Perfusion and Heart Valve businesses.

Sean served as U.S. Vice President of Sales & Marketing at Covidien (now Medtronic), where he held full P&L responsibility for three divisions with combined $350M annual revenue.

He was VP of Sales for a start-up, OmniSonics Medical Technologies, to establish the sales organization, develop product commercialization efforts, and initiate centers for limited post-FDA-approval market release. Prior to that, Sean was at DataScope (now Maquet), where he was VP Sales for both the Vascular Division as well as the Interventional Products Division.

The trajectory of Sean’s career began when he joined U.S. Surgical as a Sales Representative. He held positions of increasing scope and responsibility in both sales and marketing. He gained solid experience launching and selling disposable, implantable and capital equipment across a wide range of surgical specialties.

Sean serves as an Entrepreneur in Residence for Yale Ventures as well as an advisor to Cleveland Clinic Innovations & Ventures.

Ian Dawson

(727) 313-2977 | [email protected] | vCard

Ian is an experienced business and marketing professional with extensive US and international leadership experience. He has served as a member of several executive leadership teams, and has lived and worked in the US, UK, and Switzerland.

His broad experience includes Medical Devices, Pharmaceuticals, Animal Health and B2B Retail products. He has worked for multinational companies such as Zimmer Biomet, Smith & Nephew, Stryker, Idexx, and Glaxo, but has also real-world experience of working in startups, small and mid cap businesses, such as MAKO Surgical Corp and Integrum.

Ian has consulted for several blue chip and startup companies in the life sciences market, particularly in the areas of orthopaedics, robotics, wound management, diagnostics, and surgical devices – covering capital, implantable and disposable products.

Ian has a consistent international track record of growing revenues, profits, and market shares through application of creative business models and marketing fundamentals. Having lived and worked in different countries, he truly understands the importance of understanding the different customer needs and market dynamics from market to market, if companies are to maximize brand acceptance and sales results.

Ian has held a number of senior marketing roles for global medical device companies. These most recently include Integrum, a Swedish company pioneering the concept of osseointegration as a transformational technology for amputees where he was VP Global Marketing, with a particular focus on establishing the technology as an enabling and disruptive alternative to the traditional method of amputee use of socket technologies.

As Director of Strategy for Robotics at Zimmer Biomet, Ian led the market entry planning, and commercialization, for the company’s Orthopedic robotic platform. This included developing a customer segmentation strategy as well as recruiting and leading a team of Clinical Program Managers to accelerate market adoption and ensure early customer success.

He was SVP Marketing for Mako Surgical Corp, which was acquired in 2013 by Stryker, where he refocused the marketing efforts on the key surgeon audience as well as C-Suite and patient customers. Previously, he was VP Marketing for Smith & Nephew’s North American Wound Management business where he successfully led the turnaround marketing efforts for the device and dressing portfolios that had been underperforming compared to competitive peers.

In addition to working for established companies Ian has also worked for several startups including Idexx, now the global leader in animal health diagnostics, where he was responsible for European distributor management and part of the team that set up the UK subsidiary.

Ian has consulted for several blue chip and startup companies in the life sciences market, particularly in the areas of orthopaedics, robotics, wound management, diagnostics, and surgical devices – covering capital, implantable and disposable products.

John Hart

(201) 280-6904 | [email protected] | vCard

John is an experienced executive in the healthcare industry having held general management, marketing, sales, business development and manufacturing leadership positions in Fortune 500, VC and PE-backed medical device and life science companies.

During John’s career, he has held senior leadership and growth positions in global MedTech organizations including U.S. Surgical (now Medtronic), Stryker Corporation and Conmed Corporation where he was VP and General Manager. VP of Global Marketing and VP of Sales for billion-dollar divisions with direct responsibility for over 1,000 people.

Most recently, John was President & CEO and a Board Director for two medical device companies, Southern Spine, an innovative MIS spinal implant company and SCB, a best-in-class rapid infusion blood pump company for trauma and transplant centers.

Throughout his career, John has been a recognized leader within the industry for his ability to lead sales, profit and SOM growth, expand markets, drive new product innovation, lead strategic planning and execution, M&A and implementation, improve operational efficiency, and grow talented people.

John joined 360 Life Science Advisors in 2024 as a Partner and is a proven, hands-on executive who has led significant sales and profit growth, new market opportunities, leadership transformations, turnarounds, M&A, and strategic planning processes and execution in Fortune 500, Private Equity and Venture Capital-backed firms in a number of medical device markets.  Most recently, John was President & CEO and Board Director for two companies:  Southern Spine LLC, a minimally invasive spinal implant company and Smisson-Cartledge Biomedical LLC, a rapid infusion blood pump company used in trauma centers and transplant cases. 

Prior, John was part of the turnaround team at Conmed Corporation (CNMD/NYSE) recruited by their CEO who helped take the company to their next levels of sales and profit growth.  Mr. Hart was the Vice President & General Manager for the Cardiology & Critical Care Division which he led from historically negative to double digit sales and profit growth, and Healthcare Solutions the corporate contracting team representing $500 million in U.S. Sales that landed more IDN, GPO and Government contracts including Novation, Kaiser and The Mayo Clinic that helped increase sales, profits and the company stock price.  In 2006, John co-founded and started up SurgiQuest, Inc. in Connecticut as its first President & CEO which was an innovative Venture Capital-backed laparoscopic surgical company that was sold to Conmed in 2016 for $265M. 

Prior, John was the Chief Operating Officer for ISTO Technologies, Inc., a venture backed company in St. Louis focused on biologics and cartilage regeneration for the knee and spine.  Mr. Hart was President & CEO for Vidar Systems Corporation, a Private Equity-owned, leading digital medical imaging company located in Herndon, Virginia.  Both companies achieved successful M&A exits with ISTO merging with Arteriocyte to become ISTO Biologics, and Vidar being sold to a strategic company, 3D Systems. 

Previously, Mr. Hart held senior executive positions in Fortune 500 companies, including Stryker Orthopaedics (Stryker Corporation – SYK: NYSE) and U.S. Surgical Corporation (Covidien – now Medtronic – MDT: NYSE) where he was Vice President & General Manager, V.P. of Global Marketing and V.P. of Sales for multi-billion-dollar divisions.  John led the $1 Billion Knee Business Unit for Stryker Orthopedics with P&L responsibility and the innovative commercial development and launches of the new Triathlon™ Knee System and Simplex™ Tobra Bone Cement leading to significant Stryker sales growth for many years.  At U.S. Surgical/Covidien, Mr. Hart led the $1.2 Billion Auto Suture Division with P&L responsibility where he helped land the first sole source GPO contract in company history with Consorta that led to significant sales and profit growth.  John has led divisions with over $2.5 Billion in global revenues and has held direct responsibility for over 1,000 people. 

John began his career in operations management and sales positions with the Ethicon Inc. division of Johnson & Johnson (JNJ: NYSE) and has held marketing leadership and business development positions with CR Bard (now B-D), Kimberly Clark PHC (now O&M) and Abiomed (now J&J).  Mr. Hart has mentored and developed numerous people in his career who have ultimately led companies, divisions, marketing, sales and business development teams.

John has been involved in a number of cutting-edge medical technologies throughout his career including coronary angioplasty and stenting, surgical stapling, laparoscopic surgery and robotics, minimally invasive surgery, orthopedic implants and instrumentation, MIS spine surgery, ortho-biologics and cartilage regeneration, PPE, wireless monitoring and digital medical imaging. 

John is on the Board of Directors for Virginia Bio and NL Capital Ventures and has been a guest lecturer on “Leadership and Management” at Georgetown University, George Mason University, The College of NJ, SNHU and the NIH.  Mr. Hart has a BS from The College of New Jersey in Ewing, NJ and an MBA from Southern New Hampshire University in Manchester, NH.

Connect with our team to see how 360 Life Sciences Advisors can help you.